However, when the authors analyzed ATG9A mRNA levels and correlated them with clinicopathological characteristics (ER, PR, or HER2 status), they only demonstrated a significantly lower ATG9A expression in the HER2+ subtype of breast cancers. The gene discussed is ESR1; the disease is breast carcinoma.